Judith B. Raimbourg - Publications

Parkinsonism as a Potential Neurologic Immune-Mediated Adverse Event of Immune Checkpoint Inhibitors.

Journal: Neurology(R) neuroimmunology & neuroinflammation

Published: August 10, 2026

Ivonescimab in combination with chemotherapy in advanced or metastatic gastric cancer (GC) or esophagogastric junction cancer (EGJC): The UCGI 52 - GRACIE trial.

Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

Published: July 24, 2026

Combined emphysema and cancer, from radiology to prognosis in patients treated by immunotherapy: An ancillary study of a prospective multicenter phase II IFCT-1802 SAVIMMUNE.

Journal: Respiratory medicine and research

Published: May 19, 2026

Antiangiogenic therapies in gastric cancer: future directions for 2026 and beyond: an UNICANCER gastrointestinal group (UCGI) perspective.

Journal: Cancer treatment reviews

Published: May 04, 2026

Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: May 01, 2026

Circulating epigenetic and epitranscriptomic biomarkers identify EGFR status, predict TKI response and reveal therapeutic vulnerabilities in NSCLC.

Journal: Scientific reports

Published: March 09, 2026

Phase Ib multicenter study of anti-TIM-3 (S095018/Sym023) in combination with anti-PD-1 (Sym021) in patients with advanced/metastatic recurrent biliary tract cancer.

Journal: Journal for immunotherapy of cancer

Published: February 09, 2026

A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics, and pharmacodynamics of OSE-279, an anti-PD-1 monoclonal antibody in patients with advanced solid tumours.

Journal: European journal of cancer (Oxford, England : 1990)

Published: January 02, 2026

Long-Term Response and Survival in Extensive-Stage SCLC Receiving Atezolizumab Plus Chemotherapy in a Real-World Setting: IFCT-1905 CLINATEZO.

Journal: JTO clinical and research reports

Published: November 14, 2025

Telisotuzumab Adizutecan (ABBV-400), a Novel c-Met-Targeting Antibody-Drug Conjugate: First-in-Human Results in Advanced Gastric/Gastroesophageal Junction Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: October 03, 2025

Evaluation of the return-to-work rate in systemically treated non-small cell lung cancer patient

Journal: Bulletin du cancer

Published: September 12, 2025

Tackling a caveat of the FLAURA trial and building solid evidence for frail patients in thoracic oncology.

Journal: Translational lung cancer research

Published: July 04, 2025